Assessment of Acute and Chronic Pharmacological Effects on Energy Expenditure and Macronutrient Oxidation in Humans: Responses to Ephedrine

por Napolitano, Antonella, Murgatroyd, Peter R., Finer, Nick, Hussey, Elizabeth K., Dobbins, Robert, O'Rahilly, Steve, Nunez, Derek J. R.
Publicado 2011

Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

por Hussey, Elizabeth K, Kapur, Anita, O’Connor-Semmes, Robin, Tao, Wenli, Rafferty, Bryan, Polli, Joseph W, James, Charles D, Dobbins, Robert L
Publicado 2013

Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

por Dobbins, Robert, Hussey, Elizabeth K., O’Connor-Semmes, Robin, Andrews, Susan, Tao, Wenli, Wilkison, William O., Cheatham, Bentley, Sagar, Katare, Hanmant, Barkate
Publicado 2021

Remogliflozin Etabonate, a Selective Inhibitor of the Sodium-Glucose Transporter 2, Improves Serum Glucose Profiles in Type 1 Diabetes

por Mudaliar, Sunder, Armstrong, Debra A., Mavian, Annie A., O’Connor-Semmes, Robin, Mydlow, Patricia K., Ye, June, Hussey, Elizabeth K., Nunez, Derek J., Henry, Robert R., Dobbins, Robert L.
Publicado 2012

First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 d...

por Kapur, Anita, O’Connor-Semmes, Robin, Hussey, Elizabeth K, Dobbins, Robert L, Tao, Wenli, Hompesch, Marcus, Smith, Glenn A, Polli, Joseph W, James Jr, Charles D, Mikoshiba, Imao, Nunez, Derek J
Publicado 2013